FDA approves Lymphoseek for head and neck cancer determination
The US Food and Drug Administration approved a new use for Lymphoseek (technetium 99m tilmanocept) injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body’s head and neck region.
In 2013, Lymphoseek was approved to help identify lymph nodes closest to a primary tumour in patients with breast cancer or melanoma. Lymph nodes filter lymphatic fluid that flows from the body’s tissues. This fluid may contain cancer cells, especially if the fluid drains a part of the body containing a tumour. By surgically removing and examining the lymph nodes that drain a tumour, a procedure called a biopsy, doctors can sometimes determine if a cancer has spread.
With this approval, Lymphoseek can now be used to guide testing of lymph nodes closest to a primary tumour for cancer, called a ‘sentinel’ lymph node biopsy, in patients with cancer of the head and neck. This new indication will allow for the option of more limited lymph node surgery in patients with sentinel nodes negative for cancer. “For some patients with head and neck cancer, removal and pathological examination of lymph nodes draining a primary tumour is an important diagnostic evaluation,” said , Director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research.
For this new indication, Lymphoseek’s safety and effectiveness were established in a clinical trial of 85 patients with squamous cell carcinoma of the lip, oral cavity, and skin. All patients were injected with Lymphoseek. Surgeons subsequently removed suspected lymph nodes those identified by Lymphoseek and those based upon tumour location and surgical practice for pathologic examination. Results showed that Lymphoseek guided sentinel lymph node biopsy accurately determined if the cancer had spread through the lymphatic system.
EP News Bureau – Mumbai